Fish, marine n-3 polyunsaturated fatty acids and coronary heart disease: a minireview with focus on clinical trial data.
In this paper, we will briefly deal with the background for the possible effects of long-chain marine n-3 (also called omega-3) polyunsaturated fatty acids (PUFA) in coronary heart disease (CHD) and then focus on findings from clinical trials in humans. We will not deal with effects of alpha-linolenic acid, the non-marine type of n-3 PUFA derived from plant oils.
Schmidt
Erik Berg
EB
Department of Cardiology, Center for Cardiovascular Research, Aalborg Sygehus, Arhus University Hospitals, Denmark. ebs@dadlnet.dk
Rasmussen
Lars Hvilsted
LH
Rasmussen
Jeppe Grøndahl
JG
Joensen
Albert Marni
AM
Madsen
Martin Bruun
MB
Christensen
Jeppe Hagstrup
JH
D000818:Animals; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000178:diet therapy* / Q000517:prevention & control; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage* / Q000097:blood; D005395:Fish Oils / Q000008:administration & dosage / Q000737:chemistry; D005399:Fishes; D006801:Humans; D012307:Risk Factors
D015525:Fatty Acids, Omega-3; D005395:Fish Oils